Signaling by Type I Interferons in Immune Cells: Disease Consequences

Markella Zannikou; Eleanor N. Fish; Leonidas C. Platanias

doi:10.3390/cancers16081600

Cancers (Apr 2024)

Signaling by Type I Interferons in Immune Cells: Disease Consequences

Markella Zannikou,
Eleanor N. Fish,
Leonidas C. Platanias

Affiliations

Markella Zannikou: Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, 303 East Superior Ave., Chicago, IL 60611, USA
Eleanor N. Fish: Toronto General Hospital Research Institute, University Health Network, 67 College Street, Toronto, ON M5G 2M1, Canada
Leonidas C. Platanias: Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, 303 East Superior Ave., Chicago, IL 60611, USA

DOI: https://doi.org/10.3390/cancers16081600
Journal volume & issue: Vol. 16, no. 8
p. 1600

Abstract

Read online

This review addresses interferon (IFN) signaling in immune cells and the tumor microenvironment (TME) and examines how this affects cancer progression. The data reveal that IFNs exert dual roles in cancers, dependent on the TME, exhibiting both anti-tumor activity and promoting cancer progression. We discuss the abnormal IFN signaling induced by cancerous cells that alters immune responses to permit their survival and proliferation.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords